GlobalData on MSN2d
Tumour-on-chip model could help discover pancreatic cancer therapiesA team of German scientists and biotech company Dynamic42 have jointly developed a ‘tumour-on-chip’ model of pancreatic ...
Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...
The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer ...
Through this study, we aim to offer a new, innovative treatment to patients,” medical oncologist Dr. John Lenehan said.
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP ...
The statement unites the cancer community in opposing recent executive actions and calling on both the administration and ...
Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effectsRamat Gan, Israel, March 03, ...
Dr. Makary argues for more humility from the medical establishment and common sense when reviewing experimental drugs for ...
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...
Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback